Outlook Therapeutics Q2 adjusted EPS misses analyst expectations

Outlook Therapeutics

15/05/2026 21:17

Overview

US biopharmaceutical firm's fiscal Q2 adjusted EPS missed analyst expectations

Unit sales of LYTENAVA in Europe fell 10% quarter-over-quarter, but have trended upward early in Q3

Company awaits FDA decision on ONS-5010 following formal dispute resolution meeting

Outlook

Company expects FDA decision on ONS-5010 in May 2026

Company targets 2027 launch of LYTENAVA in Switzerland, subject to regulatory approval

Outlook Therapeutics plans expansion into Netherlands and Ireland later in 2026

Result Drivers

EUROPEAN SALES DECLINE - Unit sales of LYTENAVA in Europe fell about 10% from the prior quarter, though company said sales trended upward early in Q3

COST REDUCTION EFFORTS - Company said it has taken steps to reduce costs in Europe to improve margins in future quarters

Company press release: ID:nGNX3pXvHl

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Miss
-$0.16
-$0.12 (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Outlook Therapeutics Inc is $6.00, about 2,472.9% above its May 14 closing price of $0.23

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)